Safety

[키워드] 95% CI adverse event adverse events age all-cause mortality anti-IL6 approach articles available data average baseline benefit Bia blocking agent blocking agents Brazil can not Care certainty certainty of evidence China clinical Clinical improvement Cochrane COVID-19 Study Register collected data conducted coronavirus disease Coronavirus disease 2019 COVID-19 Critical Critical disease Data collection death defined disease disease severity Efficacy and safety eight evaluate evaluated Evidence excluded FIVE Follow-up France Health Organization heterogeneity hospital discharge identify IL-6 IL-6 blocking Immune system dysfunction immunosuppressive incidence Inclusion individual individual patient data meta-analyses Inflammation interleukin interleukin 6 interleukin 6 (IL-6 Intubated intubated patient intubated patients Italy male mechanical ventilation Meta-analysis methodology Mild moderate Mortality multicentre nine no increase not intubated organ support Other outcomes outcome outcomes oxygen participant Participants Patient patient data patients with COVID-19 peer-reviewed people with COVID-19 Placebo platform Platform trial progression proportion protocol randomised randomised controlled trial Randomised controlled trials ranged RCT RCTs reduce Registered registry reported risk of bia Safety sarilumab score searched Selection Serious Adverse Event Serious Adverse Events Seven severe coronavirus disease severity siltuximab standard care Standard of care subgroups of patient systematic review Tocilizumab Tolerance Treatment Trial trial participant trial participants trials unlikely USA WHO World Health Organization
[DOI] 10.1002/14651858.CD013881 PMC 바로가기 [Article Type] Meta-Analysis